Figures & data
Fig. 1 Study population. Eligibility criteria were ≥15 years, documented treatment interruption of ≥21 days (between January 2008 and November 2009), resumption of ART. In total, patient characteristics of 347 patients were analysed, 147 B2C forms were entered into an MSAccess database and 26 in-depth interviews were conducted for descriptive analysis and to gain a further understanding of reasons for treatment interruption.
ART: Antiretroviral therapy; B2C: Back-to-Care; EDS: Electronic data system; LTFU: Lost-to-Follow up
![Fig. 1 Study population. Eligibility criteria were ≥15 years, documented treatment interruption of ≥21 days (between January 2008 and November 2009), resumption of ART. In total, patient characteristics of 347 patients were analysed, 147 B2C forms were entered into an MSAccess database and 26 in-depth interviews were conducted for descriptive analysis and to gain a further understanding of reasons for treatment interruption.ART: Antiretroviral therapy; B2C: Back-to-Care; EDS: Electronic data system; LTFU: Lost-to-Follow up](/cms/asset/8b9e9fc6-7392-4ad3-a84a-185fffb21c00/zgha_a_11818022_f0001_ob.jpg)
Fig. 2 Reasons for treatment interruption. Relative frequency of reasons for treatment interruption as stated by patients in the B2C form n=147; multiple reasons per patient possible. Additional categories exceeding the scope of the pre-defined categories were derived from the comment field and are marked with a star: *.
B2C: Back-to-Care.
![Fig. 2 Reasons for treatment interruption. Relative frequency of reasons for treatment interruption as stated by patients in the B2C form n=147; multiple reasons per patient possible. Additional categories exceeding the scope of the pre-defined categories were derived from the comment field and are marked with a star: *.B2C: Back-to-Care.](/cms/asset/95750bd8-09f2-45f9-9629-6b9a5759dbdd/zgha_a_11818022_f0002_ob.jpg)
Table 1 Respondents’ characteristics: In-depth interview (n=26)
Table 2 Factors supporting with drug adherence and retention in care in patients with documented treatment interruption (in-depth interviews; n=26)
Table 3 Reasons for treatment interruption (in-depth interviews; n=26)